

Supplementary Prospectus: dated 23 July 2019



**AB SVERIGES SÄKERSTÄLLDA OBLIGATIONER
(publ) (THE SWEDISH COVERED BOND
CORPORATION)**

(Incorporated with limited liability in the Kingdom of Sweden)

€16,000,000,000

Euro Medium Term Covered Note Programme

This Supplement (the “Supplement”) constitutes a supplementary prospectus for the purposes of Article 16 of Directive 2003/71/EC (as amended or superseded) (the “Prospectus Directive”) as implemented in the Republic of Ireland by the Prospectus (Directive 2003/71/EC) Regulations 2005, as amended and is prepared in connection with the Euro Medium Term Covered Note Programme (the “Programme”) established by AB Sveriges Säkerställda Obligationer (publ) (The Swedish Covered Bond Corporation) (the “Issuer”). This Supplement is supplemental to, and should be read in conjunction with, the Prospectus relating to the Programme dated 6 March 2019, as supplemented by the Supplementary Prospectus dated 28 March 2019 (the “Prospectus”), which together comprise a base prospectus for the purposes of Article 5.4 of the Prospectus Directive. Terms defined in the Prospectus have the same meaning when used in this Supplement.

This Supplement has been approved by the Central Bank of Ireland as a competent authority under the Prospectus Directive. The Central Bank of Ireland only approves this Supplement as meeting the requirements imposed under Irish and European Union law pursuant to the Prospectus Directive. Such approval relates only to the Notes which are to be admitted to trading on a regulated market for the purposes of Directive 2014/65/EC or which are to be offered to the public in any Member State of the European Economic Area.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge and belief of the Issuer (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Purpose of this Supplement

The purpose of this Supplement is (a) to incorporate by reference the unaudited interim financial statements of the Issuer for the six months ended 30 June 2019, including the audit review report thereon (the “2019 Interim Results”), (b) to update the list of members of the Board of Directors and (c) to include a new “Significant or Material Change” statement.

2019 Interim Results

On 17 July 2019, the Issuer published its Interim Report January – June 2019 (the “2019 Interim Report”) available at https://www.sbab.se/download/18.6a86aac716bf8281c2ea5/1563292675616/SCBC_H1-2019_FINAL_ENG.pdf.

A copy of the 2019 Interim Report has been filed with the Central Bank of Ireland and, by virtue of this Supplement, the 2019 Interim Results (as set out on pages 6 to 20 inclusive of the Interim Report) are incorporated in, and form part of, the Prospectus. Copies of this Supplement, the Prospectus and any documents which are incorporated by reference in the Prospectus can be obtained, upon request and free of charge, from the registered office of the Issuer and from the specified office of the Principal Paying Agent for the time being in London. In addition, this Supplement and the Prospectus are also available for viewing on the website of the Central Bank of Ireland and Euronext Dublin at <http://www.ise.ie> and <https://www.centralbank.ie/regulation/industry-market-sectors/securities-markets/prospectus-regulation/prospectuses>.

Board of Directors

As of the date hereof, the Board of Directors of the Issuer is made up of the following members:

Jan Sinclair	Chairman of the Issuer and Chairman of the Board of Directors of SBAB
Jane Lundgren Eriksson	Board Member of the Issuer and SBAB

Significant or Material Change

No material adverse change in the prospects of the Issuer has occurred since 31 December 2018. No significant change in the financial or trading position of the Issuer has occurred since 30 June 2019.

General Information

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in, or incorporated by reference into, the Prospectus, the statements in (a) above will prevail.

To the extent that any document or information incorporated by reference itself incorporates any information by reference, either expressly or impliedly, such information will not form part of this Supplement for the purposes of the Prospectus Directive, except where such information or documents are stated within this Supplement as specifically being incorporated by reference or where this Supplement is specifically defined as including such information.

Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Prospectus since the publication of the Prospectus.